Most of the thousands of new anti-cancer medicines in development will fail clinical trials, after millions of dollars and more than 10 years are spent for testing and review.
But this approach won’t work to quickly and effectively find cancer treatments, said Dr. William Nelson, director of the Johns Hopkins Kimmel Cancer Center.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.